Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AAPG NASDAQ:AUTL NYSE:BHVN NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.60+2.9%$22.10$16.92▼$48.45$1.60B-0.059,674 shs11,877 shsAUTLAutolus Therapeutics$1.56$1.57$1.18▼$2.70$415.20M2.021.54 million shs1.02 million shsBHVNBiohaven$11.34-0.2%$10.00$7.48▼$18.57$1.71B1.352.82 million shs2.36 million shsSLSSELLAS Life Sciences Group$7.83+1.0%$6.22$1.39▼$9.51$1.52B2.510.00 million shs4.06 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-1.96%-6.40%-20.05%-29.96%-42.49%AUTLAutolus Therapeutics+5.41%-6.02%-2.50%+8.33%-30.36%BHVNBiohaven+2.00%-0.24%+23.15%+18.55%-27.48%SLSSELLAS Life Sciences Group+8.39%-14.27%+48.47%+44.32%+416.67%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAPGAscentage Pharma Group International$17.60+2.9%$22.10$16.92▼$48.45$1.60B-0.059,674 shs11,877 shsAUTLAutolus Therapeutics$1.56$1.57$1.18▼$2.70$415.20M2.021.54 million shs1.02 million shsBHVNBiohaven$11.34-0.2%$10.00$7.48▼$18.57$1.71B1.352.82 million shs2.36 million shsSLSSELLAS Life Sciences Group$7.83+1.0%$6.22$1.39▼$9.51$1.52B2.510.00 million shs4.06 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAPGAscentage Pharma Group International-1.96%-6.40%-20.05%-29.96%-42.49%AUTLAutolus Therapeutics+5.41%-6.02%-2.50%+8.33%-30.36%BHVNBiohaven+2.00%-0.24%+23.15%+18.55%-27.48%SLSSELLAS Life Sciences Group+8.39%-14.27%+48.47%+44.32%+416.67%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAPGAscentage Pharma Group International 3.20Buy$46.43163.80% UpsideAUTLAutolus Therapeutics 2.89Moderate Buy$8.75460.90% UpsideBHVNBiohaven 2.71Moderate Buy$22.2796.30% UpsideSLSSELLAS Life Sciences Group 2.00Hold$10.0027.71% UpsideCurrent Analyst Ratings BreakdownLatest AUTL, BHVN, SLS, and AAPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026AAPGAscentage Pharma Group International Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/10/2026AAPGAscentage Pharma Group International B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.006/2/2026BHVNBiohaven Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/27/2026BHVNBiohaven Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy5/26/2026BHVNBiohaven HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$10.005/14/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026AUTLAutolus Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $10.005/13/2026BHVNBiohaven Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$21.00 ➝ $18.005/5/2026BHVNBiohaven Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$23.00 ➝ $22.004/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAPGAscentage Pharma Group International$82.10M20.01N/AN/A$2.04 per share8.63AUTLAutolus Therapeutics$75.39M5.51N/AN/A$0.67 per share2.33BHVNBiohavenN/AN/AN/AN/A$0.39 per shareN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAPGAscentage Pharma Group International-$177.71MN/AN/AN/AN/AN/AN/AN/AN/AAUTLAutolus Therapeutics-$287.53M-$1.09N/AN/AN/A-311.98%-128.59%-46.25%8/11/2026 (Estimated)BHVNBiohaven-$738.82M-$5.67N/AN/AN/AN/A-866.46%-137.99%8/10/2026 (Estimated)SLSSELLAS Life Sciences Group-$26.86M-$0.23N/AN/AN/AN/A-47.12%-42.63%8/11/2026 (Estimated)Latest AUTL, BHVN, SLS, and AAPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026AUTLAutolus Therapeutics-$0.29-$0.27+$0.02-$0.27$26.27 million$26.22 million5/12/2026Q1 2026SLSSELLAS Life Sciences Group-$0.06-$0.05+$0.01-$0.05N/AN/A5/4/2026Q1 2026BHVNBiohaven-$0.86-$0.88-$0.02-$0.88$0.27 millionN/A3/27/2026Q4 2025AUTLAutolus Therapeutics-$0.27-$0.34-$0.07-$0.34$23.92 million$24.29 million3/25/2026H2 2025AAPGAscentage Pharma Group InternationalN/A-$0.5150N/A-$0.5150N/A$24.72 million3/19/2026Q4 2025SLSSELLAS Life Sciences Group-$0.0633-$0.05+$0.0133-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAAPGAscentage Pharma Group InternationalN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAPGAscentage Pharma Group International0.571.791.77AUTLAutolus TherapeuticsN/A5.805.28BHVNBiohaven1.877.417.41SLSSELLAS Life Sciences GroupN/A17.2217.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAPGAscentage Pharma Group InternationalN/AAUTLAutolus Therapeutics72.83%BHVNBiohaven88.78%SLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipAAPGAscentage Pharma Group InternationalN/AAUTLAutolus Therapeutics25.70%BHVNBiohaven13.80%SLSSELLAS Life Sciences Group1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAPGAscentage Pharma Group International60093.33 millionN/AN/AAUTLAutolus Therapeutics330266.16 million197.75 millionOptionableBHVNBiohaven239150.56 million129.78 millionOptionableSLSSELLAS Life Sciences Group10196.63 million194.08 millionNot OptionableAUTL, BHVN, SLS, and AAPG HeadlinesRecent News About These CompaniesSLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment DisputeJune 5, 2026 | finance.yahoo.comAnalyzing SELLAS Life Sciences Group (NASDAQ:SLS) and Exelixis (NASDAQ:EXEL)June 4, 2026 | americanbankingnews.comSELLAS Life Sciences boosts liquidity through warrant exercisesJune 2, 2026 | tipranks.comJim Cramer on SELLAS: “It’s a Great Spec”June 1, 2026 | insidermonkey.comSELLAS Life Sciences Group (SLS) Is Up 21.4% After REGAL Nears Topline Readout And Cramer EndorsementMay 30, 2026 | finance.yahoo.comSLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPSMay 28, 2026 | finance.yahoo.comSellas Life Sciences: The Internal Inconsistency Of An Assumed Positive REGAL ReadoutMay 28, 2026 | seekingalpha.comSLS stock surges toward fifth weekly rise: CEO touts GPS as lifeline for elderly patients as cancer summit loomsMay 27, 2026 | msn.comSLS Stock Heads For Its Best Month This Year Ahead Of Key AML Trial ReadoutMay 26, 2026 | finance.yahoo.comSLS stock heads for their best month this year ahead of key AML trial readoutMay 26, 2026 | msn.comSellas Life Sciences: REGAL Delay May Be A Warning Sign, Not A Bullish SignalMay 22, 2026 | seekingalpha.comSLS stock jumps premarket: CEO says GPS AML data has ‘very good chance’ to beat earlier survival outcomesMay 20, 2026 | msn.comSELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?May 20, 2026 | benzinga.comSELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?May 20, 2026 | benzinga.comSLS stock rallies after hours as CEO teases leukemia study data any day nowMay 19, 2026 | msn.comSELLAS Life Sciences (SLS) Is Up 50.5% After Pivotal AML Trial Nears Readout And Adds Funding Flexibility – Has The Bull Case Changed?May 16, 2026 | uk.finance.yahoo.comSLS stock hits 4-year high: BlackRock stake boost fuels buzz around looming AML trial readoutMay 14, 2026 | msn.comSELLAS Life Sciences to Participate in Upcoming Investor ConferencesMay 14, 2026 | globenewswire.comSLS on track to clock best week in over 4 months: Retail divided between stock drop or multibagger status amid upcoming leukemia trial readoutMay 13, 2026 | msn.comSELLAS rises as Q1 update suggests lead program nears final analysisMay 13, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAUTL, BHVN, SLS, and AAPG Company DescriptionsAscentage Pharma Group International NASDAQ:AAPG$17.60 +0.49 (+2.86%) Closing price 04:00 PM EasternExtended Trading$17.73 +0.13 (+0.74%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.Autolus Therapeutics NASDAQ:AUTL$1.56 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.59 +0.03 (+1.92%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Biohaven NYSE:BHVN$11.34 -0.03 (-0.24%) Closing price 03:59 PM EasternExtended Trading$11.40 +0.06 (+0.52%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.SELLAS Life Sciences Group NASDAQ:SLS$7.83 +0.08 (+1.03%) Closing price 04:00 PM EasternExtended Trading$7.94 +0.11 (+1.46%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
